Advertisement

Restrictive Cardiomyopathy

  • Aalap Chokshi
  • Amanda R. Vest
Chapter
Part of the Clinical Cases in Cardiology book series (CCC)

Abstract

A 57 year-old female with a history of nonischemic cardiomyopathy was referred for management of heart failure. Five months ago, the patient was evaluated for 2 months of fevers, dyspnea on exertion and lower extremity edema. A transthoracic echocardiogram (TTE) was completed which revealed a left ventricular ejection fraction (LVEF) of 20% with global hypokinesis. A nuclear stress test was normal. A repeat TTE 1 month later showed improved LVEF to 35–40%.

Keywords

Amyloidosis Restrictive cardiomyopathy 

References

  1. 1.
    Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012;1:e000364.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol. 2015;12:91–102.CrossRefPubMedGoogle Scholar
  3. 3.
    Castaño A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2015;20:163–78.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Dispenzieri A, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:3751–7.CrossRefGoogle Scholar
  5. 5.
    Dubrey SW, Comenzo RL. Amyloid diseases of the heart: current and future therapies. QJM. 2012;105:617–31.CrossRefPubMedGoogle Scholar
  6. 6.
    Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. 99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195–201.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Phelan D, Collier P, Thavendiranathan P, Popovic ZB, Hanna M, Plana JC, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98(19):1442–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Phelan D, Thavendiranathan P, Popovic Z, Collier P, Griffin B, Thomas JD, et al. Application of a parametric display of two-dimensional speckle-tracking longitudinal strain to improve the etiologic diagnosis of mild to moderate left ventricular hypertrophy. J Am Soc Echocardiogr. 2014;27(8):888–95.CrossRefPubMedGoogle Scholar
  9. 9.
    Koyama J, Ikeda S, Ikeda U. Echocardiographic assessment of the cardiac amyloidoses. Circ J. 2015;79:721–34.CrossRefPubMedGoogle Scholar
  10. 10.
    Estep JD, et al. Heart transplantation and end-stage cardiac amyloidosis: a review and approach to evaluation and management. Methodist Debakey Cardiovasc J. 2012;8:8–16.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Fikrle M, et al. The diagnostic performance of cardiac magnetic resonance in detection of myocardial involvement in AL amyloidosis. Clin Physiol Funct Imaging. 2014;36:218.  https://doi.org/10.1111/cpf.12216.CrossRefPubMedGoogle Scholar
  12. 12.
    Falk RH. Cardiac amyloidosis: a treatable disease, often overlooked. Circulation. 2011;124:1079–85.CrossRefPubMedGoogle Scholar
  13. 13.
    Varr BC, et al. Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm. 2014;11:158–62.CrossRefPubMedGoogle Scholar
  14. 14.
    Sanchorawala V. Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol. 2006;1:1331–41.CrossRefPubMedGoogle Scholar
  15. 15.
    Wechalekar AD, et al. Guidelines on the management of AL amyloidosis. Br J Haematol. 2015;168:186–206.CrossRefPubMedGoogle Scholar
  16. 16.
    Gertz MA, et al. First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:1097.  https://doi.org/10.1200/JCO.2015.63.6530.CrossRefGoogle Scholar
  17. 17.
    Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2015;387:2641.  https://doi.org/10.1016/s0140-6736(15)01274-x.CrossRefPubMedGoogle Scholar
  18. 18.
    Herlenius G, Wilczek HE, Larsson M, Ericzon B-G, Familial Amyloidotic Polyneuropathy World Transplant Registry. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation. 2004;77:64–71.CrossRefPubMedGoogle Scholar
  19. 19.
    Maurer MS, et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015;8:519–26.CrossRefPubMedGoogle Scholar
  20. 20.
    Berk JL, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658–67.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Coelho T, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819–29.CrossRefPubMedGoogle Scholar
  22. 22.
    Swiecicki PL, et al. Left ventricular device implantation for advanced cardiac amyloidosis. J Heart Lung Transplant. 2013;32:563–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Grupper A, et al. Role of ventricular assist therapy for patients with heart failure and restrictive physiology: improving outcomes for a lethal disease. J Heart Lung Transplant. 2015;34:1042–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Dubrey SW, Burke MM, Hawkins PN, Banner NR. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant. 2004;23:1142–53.CrossRefPubMedGoogle Scholar
  25. 25.
    Lacy MQ, et al. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. J Heart Lung Transplant. 2008;27:823–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Dey BR, et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation. 2010;90:905–11.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Varr BC, et al. Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies. J Heart Lung Transplant. 2012;31:325–31.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of CardiologyMount Sinai HospitalNew YorkUSA
  2. 2.Division of CardiologyTufts Medical CenterBostonUSA

Personalised recommendations